Los Angeles, CALIFORNIA65 Active Studies

Heart Attack Clinical Trials in Los Angeles, CALIFORNIA

Find 65 actively recruiting heart attack clinical trials in Los Angeles, CALIFORNIA. Connect with local research sites and explore new treatment options.

65
Active Trials
51
Sponsors
21,571
Enrolling

Recruiting Heart Attack Studies in Los Angeles

RecruitingLos Angeles, CALIFORNIANCT03013998

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)."...

2,000 participants
Beat AML, LLC
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06972056

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive me...

1,335 participants
Mayo Clinic
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05125302

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Mig...

1,059 participants
AbbVie
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04396574

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will la...

1,000 participants
Eli Lilly and Company
View Study Details
RecruitingLos Angeles, CALIFORNIANCT07018700

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine d...

990 participants
Merz Therapeutics GmbH
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05681351

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG....

800 participants
Ionis Pharmaceuticals, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT07018713

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine da...

780 participants
Merz Therapeutics GmbH
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

727 participants
Immunocore Ltd
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06047444

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine. A migraine is a headache with severe thr...

720 participants
Ipsen
View Study Details
RecruitingLos Angeles, CALIFORNIANCT01804686

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolle...

700 participants
Janssen Research & Development, LLC
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04064060

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the t...

665 participants
Celgene
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06073821

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)...

652 participants
BeiGene
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04961567

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active...

540 participants
Biogen
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04895241

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active...

540 participants
Biogen
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05617677

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population....

490 participants
Bristol-Myers Squibb
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06617325

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of mo...

450 participants
UCB Biopharma SRL
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04623541

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refract...

424 participants
Genmab
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04065399

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled...

413 participants
Syndax Pharmaceuticals
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05639114

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC)...

406 participants
Novartis Pharmaceuticals
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05429632

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial....

366 participants
Priothera SAS
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06233799

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing...

360 participants
National Institute on Drug Abuse (NIDA)
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06411249

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ...

350 participants
GlaxoSmithKline
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05554406

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with...

335 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLos Angeles, CALIFORNIANCT03331198

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to de...

320 participants
Juno Therapeutics, a Subsidiary of Celgene
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05948566

Strategy for Improving Stroke Treatment Response

SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alp...

300 participants
Translational Sciences, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05878717

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lun...

300 participants
GlaxoSmithKline
View Study Details
RecruitingLos Angeles, CALIFORNIANCT00775476

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack ...

290 participants
State University of New York - Upstate Medical University
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04067336

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Pha...

263 participants
Kura Oncology, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06846671

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venet...

250 participants
BeiGene
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06368817

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy us...

240 participants
Children's Oncology Group
View Study Details
RecruitingLos Angeles, CALIFORNIANCT03850574

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelod...

240 participants
Aptose Biosciences Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05082519

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients w...

240 participants
Etan Orgel
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04256317

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

236 participants
Taiho Oncology, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05600426

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatme...

234 participants
Boston Children's Hospital
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05641688

[18F]PI-2620 Phase 3 Histopathological Study

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Al...

200 participants
Life Molecular Imaging Ltd
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit...

147 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06137118

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in par...

142 participants
AstraZeneca
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04996875

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Asso...

140 participants
Cogent Biosciences, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06514794

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a ther...

125 participants
Wugen, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06428019

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutini...

120 participants
AbbVie
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06384261

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to v...

120 participants
OncoVerity, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05929729

Iron Deficiency Anemia (IDA) and the Brain

This is a trial with an observational and an interventional arm, in patients with moderate to severe anemia and control subjects. The main purposes of this study is to phenotype the scope of neurocogn...

120 participants
Children's Hospital Los Angeles
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04119050

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA)....

111 participants
Janssen Research & Development, LLC
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05835310

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE...

100 participants
AstraZeneca
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04143724

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

This is a Phase 2a study to evaluate the safety and pharmacokinetics (PK) of luspatercept in pediatric participants with β-thalassemia. The study will be conducted in 2 parts for both transfusion-dep...

99 participants
Celgene
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05848687

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets...

90 participants
Tanja Andrea Gruber
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05490446

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participant...

82 participants
Agios Pharmaceuticals, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT02981628

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed...

80 participants
Children's Oncology Group
View Study Details
RecruitingLos Angeles, CALIFORNIANCT03205995

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

The purpose of this study is to evaluate the platelet count change from baseline and safety of OMS721 in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The study will also eval...

80 participants
Omeros Corporation
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04159103

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

This 3-part, Phase 1/2 study is designed to characterize the safety, tolerability, and pharmacological activity (as assessed by biomarker measurements) and to determine the selected dose of mRNA-3927 ...

77 participants
ModernaTX, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06456463

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azaci...

76 participants
Stemline Therapeutics, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05520567

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is les...

70 participants
Astellas Pharma Global Development, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04899310

A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

This is a study of mRNA-3705 in participants with isolated elevated methylmalonic acid (MMA) due to methylmalonyl-coenzyme A (CoA) mutase (MUT) deficiency. The main goal of the study is to assess safe...

63 participants
ModernaTX, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05295433

An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

The primary objective of this study is to evaluate the long-term safety of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT...

63 participants
ModernaTX, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06517641

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated....

60 participants
Medical College of Wisconsin
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05849662

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will re...

58 participants
Therapeutic Advances in Childhood Leukemia Consortium
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04150497

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...

52 participants
Cellectis S.A.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04889430

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy...

50 participants
Novartis Pharmaceuticals
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06401356

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionall...

50 participants
Novartis Pharmaceuticals
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06804603

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo...

50 participants
Vanda Pharmaceuticals
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04571138

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma

Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient,...

42 participants
Seattle Children's Hospital
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05892614

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary ob...

25 participants
aTyr Pharma, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04964518

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The st...

24 participants
Ascentage Pharma Group Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04905810

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come bac...

20 participants
Brian Jonas
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06985147

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics...

20 participants
Disc Medicine, Inc
View Study Details

About Heart Attack Clinical Trials in Los Angeles

A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.

There are currently 65 heart attack clinical trials recruiting participants in Los Angeles, CALIFORNIA. These studies are seeking a combined 21,571 participants. Research is being sponsored by Beat AML, LLC, Mayo Clinic, AbbVie and 48 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Heart Attack Clinical Trials in Los Angeles — FAQ

Are there heart attack clinical trials in Los Angeles?

Yes, there are 65 heart attack clinical trials currently recruiting in Los Angeles, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Los Angeles?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you about next steps.

Are clinical trials in Los Angeles free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Los Angeles studies also compensate for your time and travel.

What heart attack treatments are being tested?

The 65 active trials in Los Angeles are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.

Data updated March 2, 2026 from ClinicalTrials.gov